BioElectronics Files Form 15 With Securities and Exchange Commission

  • Email
  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest

FREDERICK, MD–(Marketwire – Apr 19, 2011) – BioElectronics Corp. (PINKSHEETS: BIEL), the maker of disposable drug-free anti-inflammatory devices, today announced that it has filed a Form 15 with the SEC terminating the registration of the Company’s Common Stock under Section 12(g) of the Securities Exchange Act of 1934. As a result of this filing, the Company will cease filing periodic reports with the SEC.

“The Board did not take this decision lightly. However, after consultation with our attorneys and auditors it became clear that the expense and resources necessary to meet the SEC’s reporting requirements were too much for a firm this small,” said Rick Staelin, Chairman of the BioElectronics Board. “We have decided to instead focus our limited resources on meeting FDA requirements and new marketing and sales efforts.”

About BioElectronics Corporation
BioElectronics Corporation is the award winning medical device developer and manufacturer of medical devices. Its products are ActiPatch® Therapy, for over-the-counter treatment of back pain and other musculoskeletal complaints, the Allay™ over-the-counter menstrual cycle pain therapy, and RecoveryRx for surgical procedures and wound care. The Company’s products use patented technology and provide cost-effective home care to reduce soft tissue pain and swelling. For more information, please see www.bielcorp.com.